Aesthetic Plast Surg. 2024 Feb 12. doi: 10.1007/s00266-024-03866-w. Online ahead of print.
NO ABSTRACT
PMID:38347132 | DOI:10.1007/s00266-024-03866-w
The Efficacy of Botulinum Toxin A in Treating Palmar Hyperhidrosis – a Literature Review
Maedica (Bucur). 2023 Dec;18(4):712-717. doi: 10.26574/maedica.2023.18.4.712.
ABSTRACT
Background:Palmar hyperhidrosis, a condition characterized by excessive sweating in the palms, considerably impacts the quality of life (QoL). Although various treatment modalities are available, the efficacy and safety of Botulinum toxin type A (BTX-A) needed further investigation. Methods:We conducted a literature review, with open-label, controlled trial, double-blind placebo-controlled and observational designs being eligible for inclusion, according to the PRISMA guidelines. Results:All the six selected studies consistently reported the efficacy of BTX-A in reducing symptoms of hyperhidrosis, without significant side effects. Botulinum toxin type A treatment was found to improve the QoL significantly, to reduce sweat rate and production and to have no detrimental effect on grip strength. The duration of the antisudorific effect also indicated the potential for long-term management of palmar hyperhidrosis with BTX-A. Conclusions:Our findings corroborated the effectiveness and safety of BTX-A in managing palmar hyperhidrosis across diverse patient outcomes and experiences. Botulinum toxin type A emerged as a promising treatment modality for this condition, capable of improving the QoL, reducing symptoms and offering long-term relief without significant side effects.
PMID:38348073 | PMC:PMC10859206 | DOI:10.26574/maedica.2023.18.4.712
Impostor phenomenon is a common feature among individuals with primary hyperhidrosis
SAGE Open Med. 2024 Jan 27;12:20503121231220828. doi: 10.1177/20503121231220828. eCollection 2024.
ABSTRACT
BACKGROUND: Primary hyperhidrosis consists of excessive focal sweating. Affected individuals camouflage the sweating on their body, avoiding stigmatisation. Hence, misrepresentation in social interactions is a common feature in patients with hyperhidrosis. The aim of this study was to investigate impostor phenomenon, perfectionism, self-compassion, stress and anxiety among individuals with primary hyperhidrosis.
METHODS: A cross-sectional study was conducted at our clinic among 100 participants with axillary and palmar primary hyperhidrosis. The questionnaire contained a hyperhidrosis part and Perceived Stress Scale-4, Generalised Anxiety Disorder Scale-2, Clinical Perfectionism Questionnaire-6, Self-Compassion Scale Short form and Clance Impostor Phenomenon Scale. Descriptive statistics was used for analyses of categorical variables. As data were normally distributed independent t-test and one-way analysis of variance with post hoc Tukey test were used to compare the mean values for the questionnaires with other variables. Pearson’s correlation was used, and a forward multiple linear regression model was performed to predict presence of impostor phenomenon with gender, age and other scales in this study.
RESULTS: Impostor phenomenon occurred in almost half of our patients (48%) with hyperhidrosis. While feelings of impostor phenomenon were more common in women, there was no difference between gender regarding its intensity levels (p = 0.07). In addition, we found a significant (p < 0.001) negative correlation between impostor phenomenon and self-compassion, while feelings of impostoer phenomenon increased with stress, anxiety and perfectionism (p < 0.001).
CONCLUSIONS: Feelings of impostor phenomenon was found in 48% of individuals with hyperhidrosis which indicates that it is a common feature in this patient group. Future research is warranted regarding the prevalence of impostor phenomenon in hyperhidrosis and other medical conditions, among men and women, seeking medical healthcare. Psychological interventions in hyperhidrosis may be beneficial both for the individual and in public health, by facilitating management of patients’ daily lives and saving considerable resources in healthcare regarding pharmacological interventions and medical consultations.
PMID:38283646 | PMC:PMC10822058 | DOI:10.1177/20503121231220828
Reactive Hyperhidrosis Induced by Topical Products
The Efficacy of Long-Pulsed, 1064-nm Nd:YAG Laser Versus Aluminum Chloride 20% Solution in the Treatment of Axillary Hyperhidrosis
J Lasers Med Sci. 2023 Dec 29;14:e71. doi: 10.34172/jlms.2023.71. eCollection 2023.
ABSTRACT
Introduction: Hyperhidrosis (HH) refers to uncontrollable excessive sweating that has a significant negative impact on the quality of life. The aim of this study was to compare the efficacy and safety of the long-pulsed, 1064-nm Nd:YAG laser and aluminum chloride (ALCL3 ) 20% solution in axillary HH treatment. Methods: In this single-center, within-patient comparison clinical trial, 12 patients with axillary HH were treated monthly for 3 to 4 consecutive sessions with the long-pulsed, 1064-nm Nd:YAG laser system on one axilla, while the contralateral axilla was treated with ALCL3 20 % by the patient. Treatment response was evaluated by comparing the area of sweating at the end of each session and 6 months after treatment termination using the iodine starch test. Results: Both treatments led to the reduction of HH from baseline with the mean area of sweating reduced from 109.3±36.6 to 38.3±19.8 and from 92.5±31.6 to 35.6±17.1 in laser- and ALCL3-treated axilla respectively (Both P<0.001). In the 6-month follow-up, the area of sweating was 60.6±29.2 in the laser-treated armpit and 78.3±23.6 in the ALCL3-treated side, which were 45% and 14.4% lower compared to the baseline respectively. Adverse events were temporary, and none caused each of the treatments to be discontinued. Conclusion: The long-pulsed, 1064-nm Nd:YAG laser with hair reduction setting can stand as a potential therapeutic option for axillary HH since it is as effective as ALCL3. The therapeutic effect is superior in the long term for the laser; nevertheless, the beneficial effect of both treatments may lessen the following treatment cessation.
PMID:38318217 | PMC:PMC10843241 | DOI:10.34172/jlms.2023.71
Enhancing Quality of Life: Pre- and Postoperative Assessment in Idiopathic Hyperhidrosis Patients
Cureus. 2023 Nov 28;15(11):e49588. doi: 10.7759/cureus.49588. eCollection 2023 Nov.
ABSTRACT
OBJECTIVE: This study aimed to characterize patients, describe surgical complications, and evaluate the pre- and postoperative quality of life (QOL) of individuals who underwent surgery for primary hyperhidrosis (PHH).
METHODS: A prospective, non-randomized, uncontrolled study was conducted, documenting cases of patients undergoing surgery for PHH at a reference center in La Habana, Cuba, from January 2016 to December 2022.
RESULTS: A total of 49 cases were described, with a median age of 16 years; 59.1% were female. The most common presentation was palmar-plantar-axillary, observed in 53% of cases. The palmar presentation was more frequent in female patients (p<0.05). Within 24 hours post-procedure, 85.7% of patients showed dryness in the palmar and axillary areas, with surgical complications occurring in 14.3% of cases (intercostal neuritis, pneumothorax, and hemothorax). CH of some form was recorded in 89.8% of cases. At least 30 days after the surgery, 95.9% of the patients reported a significant improvement in their QOL.
CONCLUSION: Thoracic sympathectomy is an efficient and safe method for treating hyperhidrosis in adolescents, leading to an enhanced QOL. However, this study reported a higher incidence of complications, particularly CH, compared to previous national and international studies.
PMID:38156137 | PMC:PMC10754539 | DOI:10.7759/cureus.49588
Treatment of Palmar Hyperhidrosis with Radiofrequency Microneedling-Based on Ultrasound Measurements
J Ultrasound Med. 2023 Dec 27. doi: 10.1002/jum.16402. Online ahead of print.
ABSTRACT
This study addresses the treatment of palmar hyperhidrosis, which has been difficult to manage. A new treatment has been developed using radiofrequency microneedling to reduce sweating non-surgically by ablating sweat glands. Based on ultrasound measurements of the dermis and precise microneedling damage, effective energy was applied to locate the sweat glands and disabled their function. Radiofrequency microneedling with ultrasound can safely and effectively treat hyperhidrosis in a minimally invasive way.
PMID:38149371 | DOI:10.1002/jum.16402
Predictive value of hyperhidrosis for the incidence of type 2 diabetes mellitus: A population-based cohort study in Taiwan
Kaohsiung J Med Sci. 2023 Dec 26. doi: 10.1002/kjm2.12796. Online ahead of print.
NO ABSTRACT
PMID:38146691 | DOI:10.1002/kjm2.12796
Next step in hyperhidrosis evaluation. Hyperhidrosis Quality of Life Index (HidroQol©) scores
Br J Dermatol. 2023 Dec 8:ljad485. doi: 10.1093/bjd/ljad485. Online ahead of print.
NO ABSTRACT
PMID:38063191 | DOI:10.1093/bjd/ljad485
Involvement of aquaporin 5 and Na-K-2Cl co-transporter 1 in the pathogenesis of primary focal hyperhidrosis: evidence from the primary sweat gland cell culture
Am J Physiol Cell Physiol. 2023 Dec 4. doi: 10.1152/ajpcell.00274.2023. Online ahead of print.
ABSTRACT
People with primary focal hyperhidrosis (PFH) usually have an overactive sympathetic nervous system, which can activate the sweat glands through the chemical messenger of acetylcholine. The role of aquaporin 5 (AQP5) and Na-K-2Cl co-transporter 1 (NKCC1) in PFH is still unknown. The relative mRNA and protein levels of AQP5 and NKCC1 in the sweat gland tissues of three subtypes of PFH patients (primary palmar hyperhidrosis, PPH; primary axillary hyperhidrosis, PAH; primary craniofacial hyperhidrosis, PCH) were detected with Real-Time PCR (qPCR) and Western blot. Primary sweat gland cells from healthy controls (NPFH-SG) were incubated with different concentrations of acetylcholine, and the relative mRNA and protein expression of AQP5 and NKCC1 were also detected. NPFH-SG cells were also transfected with si-AQP5 or shNKCC1, and acetylcholine stimulation-induced calcium transients were assayed with Fluo-3 AM calcium assay. Up-regulated AQP5 and NKCC1 expression were observed in sweat gland tissues, and AQP5 demonstrated a positive Pearson correlation with NKCC1 in PPH patients (r=0.66, p<0.001), PAH patients (r=0.71, p<0.001), and PCH patients (r=0.62, p<0.001). Up-regulated AQP5 and NKCC1 expression were also detected in primary sweat gland cells derived from three subtypes of PFH patients when compared with primary sweat gland cells derived from healthy control. Acetylcholine stimulation could induce the up-regulated AQP5 and NKCC1 expression in NPFH-SG cells, and AQP5 or NKCC1 inhibitions attenuated the calcium transients induced by acetylcholine stimulation in NPFH-SG cells. The dependence of ACh-stimulated calcium transients on AQP5 and NKCC1 expression may be involved in the development of PFH.
PMID:38047298 | DOI:10.1152/ajpcell.00274.2023